Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Chemnitz – page 5

209 clinical trials in Chemnitz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Chemnitz at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Chemnitz

Open in trial search

Hormone receptor positive breast cancer+1

Recruiting

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Hepatocellular carcinoma

Recruiting

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Follicular lymphoma

Recruiting

Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Non-small cell lung cancer+2

Recruiting

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Colorectal cancer metastatic

Recruiting

Study on Fruquintinib and Tislelizumab for Patients with Metastatic Colorectal Cancer Without Liver Metastases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Major depression

Recruiting

Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:(1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL
  • Sponsor:Vanda Pharmaceuticals Netherlands B.V.

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

HER2 positive gastric cancer

Recruiting

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Chemnitz

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on lymphomas and leukemias, including studies evaluating novel therapies for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and acute myeloid leukemia.

  • Multiple myeloma treatments
  • B-cell lymphoma therapies
  • Leukemia interventions

Several trials are investigating combination therapies and targeted treatments to improve patient outcomes.

02 Solid Tumor Research

Groundbreaking studies in gastric cancer and breast cancer, with particular emphasis on HER2-positive tumors and targeted therapeutic approaches.

  • Colorectal cancer treatments
  • Melanoma therapies
  • Glioblastoma interventions

Focus on personalized medicine approaches and combination treatments for various solid tumors.

03 Autoimmune Conditions

Clinical investigations of treatments for Sjögren's Syndrome and other autoimmune disorders, exploring new therapeutic options for patients.

  • Atopic dermatitis treatments
  • Prurigo nodularis studies
  • Inflammatory conditions

Evaluating novel compounds and biologics for chronic autoimmune conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.